Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.
about
MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemiaInteraction between Her2 and Beclin-1 proteins underlies a new mechanism of reciprocal regulation.EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cellsNew agents for acute myeloid leukemia: is it time for targeted therapies?FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.Identification of potential tissue-specific cancer biomarkers and development of cancer versus normal genomic classifiers.Effects of lapatinib on cell proliferation and apoptosis in NB4 cells.Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.An eco-friendly direct spectrofluorimetric method for the determination of irreversible tyrosine kinase inhibitors, neratinib and pelitinib: application to stability studies.
P2860
Q34794431-23B5E176-F76B-4249-AA45-EB8D100B5B7CQ35093305-E1489ABA-CF05-43A9-B8BE-ACEE37EB1203Q37012420-7BFA2113-B6E2-49FC-A018-792F258C2EE5Q37420045-EDA7E0E2-784A-4E70-8D55-00983E8A60ACQ37973135-001A08B8-3071-4D57-852D-318C5D212735Q38026453-3FA2E7D1-A143-43FD-AD29-8126DB55035FQ39255686-66CA24A5-C931-4DAA-A8B9-EE054B4BB91DQ42362038-2AD7958B-E31D-49C5-B3E3-2C5419961BD6Q45943755-B69B36F0-880B-4927-9396-91A97FBF5560Q48517509-AA7E3BA2-90A4-466D-AD15-84D57F2B1287Q50921811-FD2549D7-7D46-4985-B24E-10695EDE2957Q51727547-E4D03E29-7E61-496C-A92D-23E4F592E61F
P2860
Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Tyrosine kinase inhibitors for ...... leukemic mechanisms of action.
@en
Tyrosine kinase inhibitors for ...... leukemic mechanisms of action.
@nl
type
label
Tyrosine kinase inhibitors for ...... leukemic mechanisms of action.
@en
Tyrosine kinase inhibitors for ...... leukemic mechanisms of action.
@nl
prefLabel
Tyrosine kinase inhibitors for ...... leukemic mechanisms of action.
@en
Tyrosine kinase inhibitors for ...... leukemic mechanisms of action.
@nl
P2093
P50
P1476
Tyrosine kinase inhibitors for ...... leukemic mechanisms of action.
@en
P2093
André Baruchel
Claude Gardin
Cyrielle Bouteloup
Elodie Lainey
Lionel Adès
Marie Sébert
Maximilien Tailler
Simone Boehrer
Sylvain Thépot
P304
P356
10.1016/J.BCP.2011.05.011
P407
P577
2011-06-01T00:00:00Z